Repaglinide
- Generic Name
- Repaglinide
- Brand Names
- Enyglid, Gluconorm, Prandin, NovoNorm, Repaglinide Krka, Repaglinide Accord, Repaglinide Teva
- Drug Type
- Small Molecule
- Chemical Formula
- C27H36N2O4
- CAS Number
- 135062-02-1
- Unique Ingredient Identifier
- 668Z8C33LU
- Background
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood ...
- Indication
As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- Associated Conditions
- Type 2 Diabetes Mellitus
- Associated Therapies
- -
Comparison of Repaglinide and Metformin Combination Tablet Versus Repaglinide and Metformin as Separate Tablets in Healthy Volunteers
- Conditions
- Interventions
- First Posted Date
- 2009-08-14
- Last Posted Date
- 2015-03-24
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 42
- Registration Number
- NCT00959101
Comparison of the Effects of Repaglinide and Metformin on Glucose Excursions
- First Posted Date
- 2009-01-30
- Last Posted Date
- 2009-08-25
- Lead Sponsor
- Chinese PLA General Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT00832481
- Locations
- 🇨🇳
PLA General Hospital, Beijing, Beijing, China
Comparison of the Blood Sugar Lowering Effect Between Repaglinide Plus Metformin and Repaglinide Alone in Type 2 Diabetics Not Previously Treated With Oral Sugar-lowering Drugs
- Conditions
- Interventions
- First Posted Date
- 2009-01-09
- Last Posted Date
- 2017-02-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 433
- Registration Number
- NCT00819741
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Shanghai, China
Comparison of Efficacy and Safety of Repaglinide Combined With Insulin NPH Versus Biphasic Human Insulin 30 Alone in Inadequately Controlled Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2008-11-27
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 40
- Registration Number
- NCT00799448
- Locations
- 🇬🇷
Novo Nordisk Investigational Site, Athens, Greece
Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2008-10-01
- Last Posted Date
- 2017-06-05
- Lead Sponsor
- Arbelaez, Ana Maria
- Target Recruit Count
- 31
- Registration Number
- NCT00763412
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
Switch From Metformin Monotherapy to a Bitherapy With Metformin and Repaglinide
- First Posted Date
- 2008-09-03
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 906
- Registration Number
- NCT00745433
Observational Study of the Switch of Metformin Alone to Metformin Combined With Repaglinide in Type 2 Diabetes
- First Posted Date
- 2008-07-03
- Last Posted Date
- 2016-03-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2171
- Registration Number
- NCT00709917
Early Diagnosis of Diabetes Mellitus in Patients With Cystic Fibrosis
- Conditions
- Interventions
- First Posted Date
- 2008-04-21
- Last Posted Date
- 2012-07-10
- Lead Sponsor
- Mukoviszidose Institut gGmbH
- Target Recruit Count
- 73
- Registration Number
- NCT00662714
- Locations
- 🇦🇹
Universitätsklinik für Kinder- und Jugendheilkunde, Wien, Austria
🇫🇷CRCM adultes, Centre Hospitalier Lyon Sud, Lyon, France
🇫🇷APHP, CRCM pediatrique, Hopital Cochin, Paris, France
Efficacy and Safety of Repaglinide and Metformin Combined in Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-12-06
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 324
- Registration Number
- NCT00568984
- Locations
- 🇹🇭
Novo Nordisk Investigational Site, Bangkok, Thailand
Efficacy and Safety of Repaglinide, Glurenorm® and Glucobay® in Chinese Subjects With Type 2 Diabetes
- Conditions
- First Posted Date
- 2007-12-05
- Last Posted Date
- 2017-02-20
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 131
- Registration Number
- NCT00568074
- Locations
- 🇨🇳
Novo Nordisk Investigational Site, Beijing, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.